IDEAYA Biosciences, Inc. (IDYA)

Market Cap	2.13B
Revenue (ttm)	7.00M
Net Income (ttm)	-307.08M
Shares Out	87.58M
EPS (ttm)	-3.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	846,656
Open	24.50
Previous Close	24.35
Day's Range	23.81 - 24.68
52-Week Range	13.45 - 44.04
Beta	0.03
Analysts	Strong Buy
Price Target	51.36 (+111.71%)
Earnings Date	Aug 8, 2025

About ATVI

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: IDYA
• Website: https://www.ideayabio.com

Financial Performance

In 2024, IDEAYA Biosciences's revenue was $7.00 million, a decrease of -70.07% compared to the previous year's $23.39 million. Losses were -$274.48 million, 143.0% more than in 2023.

Analyst Summary

According to 13 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price target is $51.36, which is an increase of 111.71% from the latest price.

Price Target

$51.36

(111.71% upside)

Analyst Consensus: Strong Buy